Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults

Eric Simpson, Thomas Bieber, Laurent Eckert, Richard Wu, Marius Ardeleanu, Neil M H Graham, Gianluca Pirozzi, Vera Mastey

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Background The adult burden of atopic dermatitis (AD) is poorly characterized. Objective We sought to characterize AD burden in adults with moderate to severe disease from the patient's perspective. Methods Patient-reported outcomes collected at screening in a phase 2b clinical trial of dupilumab included pruritus numeric rating scale, 5-Dimension Pruritus Scale, subjective components of SCORing AD, Patient-Oriented Eczema Measure, Hospital Anxiety and Depression Scale, Dermatology Life Quality Index, and 5-Dimension EuroQol. Results Most of the 380 patients had been living with AD for nearly all their lives, whereas approximately 40% were given a diagnosis as adults; 40.3% had asthma and 60.5% had other allergic conditions. Despite 48.2% of patients using systemic therapies in the past year, patients reported problems with itch frequency (85% of patients), duration (41.5% reported itching ≥18 h/d), and severity (6.5 of 10 on numeric rating scale); 55% reported AD-related sleep disturbances 5 d/wk or more. Hospital Anxiety and Depression Scale scores suggesting clinically relevant anxiety or depression were reported by 21.8% of patients. Quality of life was impaired on Dermatology Life Quality Index and 5-dimension EuroQol. Limitations This study had limited generalizability; conclusions may not reflect those with mild AD or not participating in a clinical trial. Conclusions Adults with moderate to severe AD report multidimensional burden including disease activity, patient-reported symptoms, comorbidities, and quality-of-life impact.

Original languageEnglish (US)
Pages (from-to)491-498
Number of pages8
JournalJournal of the American Academy of Dermatology
Volume74
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Atopic Dermatitis
Clinical Trials
Pruritus
Quality of Life
Anxiety
Depression
Dermatology
SAR231893
Eczema
Comorbidity
Sleep
Asthma

Keywords

  • adults
  • atopic dermatitis
  • burden of illness
  • patient-reported outcomes
  • pruritus
  • quality of life

ASJC Scopus subject areas

  • Dermatology

Cite this

Patient burden of moderate to severe atopic dermatitis (AD) : Insights from a phase 2b clinical trial of dupilumab in adults. / Simpson, Eric; Bieber, Thomas; Eckert, Laurent; Wu, Richard; Ardeleanu, Marius; Graham, Neil M H; Pirozzi, Gianluca; Mastey, Vera.

In: Journal of the American Academy of Dermatology, Vol. 74, No. 3, 01.03.2016, p. 491-498.

Research output: Contribution to journalArticle

Simpson, Eric ; Bieber, Thomas ; Eckert, Laurent ; Wu, Richard ; Ardeleanu, Marius ; Graham, Neil M H ; Pirozzi, Gianluca ; Mastey, Vera. / Patient burden of moderate to severe atopic dermatitis (AD) : Insights from a phase 2b clinical trial of dupilumab in adults. In: Journal of the American Academy of Dermatology. 2016 ; Vol. 74, No. 3. pp. 491-498.
@article{f38bc8cfd4a14420b85a3d1c864ef8fe,
title = "Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults",
abstract = "Background The adult burden of atopic dermatitis (AD) is poorly characterized. Objective We sought to characterize AD burden in adults with moderate to severe disease from the patient's perspective. Methods Patient-reported outcomes collected at screening in a phase 2b clinical trial of dupilumab included pruritus numeric rating scale, 5-Dimension Pruritus Scale, subjective components of SCORing AD, Patient-Oriented Eczema Measure, Hospital Anxiety and Depression Scale, Dermatology Life Quality Index, and 5-Dimension EuroQol. Results Most of the 380 patients had been living with AD for nearly all their lives, whereas approximately 40{\%} were given a diagnosis as adults; 40.3{\%} had asthma and 60.5{\%} had other allergic conditions. Despite 48.2{\%} of patients using systemic therapies in the past year, patients reported problems with itch frequency (85{\%} of patients), duration (41.5{\%} reported itching ≥18 h/d), and severity (6.5 of 10 on numeric rating scale); 55{\%} reported AD-related sleep disturbances 5 d/wk or more. Hospital Anxiety and Depression Scale scores suggesting clinically relevant anxiety or depression were reported by 21.8{\%} of patients. Quality of life was impaired on Dermatology Life Quality Index and 5-dimension EuroQol. Limitations This study had limited generalizability; conclusions may not reflect those with mild AD or not participating in a clinical trial. Conclusions Adults with moderate to severe AD report multidimensional burden including disease activity, patient-reported symptoms, comorbidities, and quality-of-life impact.",
keywords = "adults, atopic dermatitis, burden of illness, patient-reported outcomes, pruritus, quality of life",
author = "Eric Simpson and Thomas Bieber and Laurent Eckert and Richard Wu and Marius Ardeleanu and Graham, {Neil M H} and Gianluca Pirozzi and Vera Mastey",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.jaad.2015.10.043",
language = "English (US)",
volume = "74",
pages = "491--498",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Patient burden of moderate to severe atopic dermatitis (AD)

T2 - Insights from a phase 2b clinical trial of dupilumab in adults

AU - Simpson, Eric

AU - Bieber, Thomas

AU - Eckert, Laurent

AU - Wu, Richard

AU - Ardeleanu, Marius

AU - Graham, Neil M H

AU - Pirozzi, Gianluca

AU - Mastey, Vera

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background The adult burden of atopic dermatitis (AD) is poorly characterized. Objective We sought to characterize AD burden in adults with moderate to severe disease from the patient's perspective. Methods Patient-reported outcomes collected at screening in a phase 2b clinical trial of dupilumab included pruritus numeric rating scale, 5-Dimension Pruritus Scale, subjective components of SCORing AD, Patient-Oriented Eczema Measure, Hospital Anxiety and Depression Scale, Dermatology Life Quality Index, and 5-Dimension EuroQol. Results Most of the 380 patients had been living with AD for nearly all their lives, whereas approximately 40% were given a diagnosis as adults; 40.3% had asthma and 60.5% had other allergic conditions. Despite 48.2% of patients using systemic therapies in the past year, patients reported problems with itch frequency (85% of patients), duration (41.5% reported itching ≥18 h/d), and severity (6.5 of 10 on numeric rating scale); 55% reported AD-related sleep disturbances 5 d/wk or more. Hospital Anxiety and Depression Scale scores suggesting clinically relevant anxiety or depression were reported by 21.8% of patients. Quality of life was impaired on Dermatology Life Quality Index and 5-dimension EuroQol. Limitations This study had limited generalizability; conclusions may not reflect those with mild AD or not participating in a clinical trial. Conclusions Adults with moderate to severe AD report multidimensional burden including disease activity, patient-reported symptoms, comorbidities, and quality-of-life impact.

AB - Background The adult burden of atopic dermatitis (AD) is poorly characterized. Objective We sought to characterize AD burden in adults with moderate to severe disease from the patient's perspective. Methods Patient-reported outcomes collected at screening in a phase 2b clinical trial of dupilumab included pruritus numeric rating scale, 5-Dimension Pruritus Scale, subjective components of SCORing AD, Patient-Oriented Eczema Measure, Hospital Anxiety and Depression Scale, Dermatology Life Quality Index, and 5-Dimension EuroQol. Results Most of the 380 patients had been living with AD for nearly all their lives, whereas approximately 40% were given a diagnosis as adults; 40.3% had asthma and 60.5% had other allergic conditions. Despite 48.2% of patients using systemic therapies in the past year, patients reported problems with itch frequency (85% of patients), duration (41.5% reported itching ≥18 h/d), and severity (6.5 of 10 on numeric rating scale); 55% reported AD-related sleep disturbances 5 d/wk or more. Hospital Anxiety and Depression Scale scores suggesting clinically relevant anxiety or depression were reported by 21.8% of patients. Quality of life was impaired on Dermatology Life Quality Index and 5-dimension EuroQol. Limitations This study had limited generalizability; conclusions may not reflect those with mild AD or not participating in a clinical trial. Conclusions Adults with moderate to severe AD report multidimensional burden including disease activity, patient-reported symptoms, comorbidities, and quality-of-life impact.

KW - adults

KW - atopic dermatitis

KW - burden of illness

KW - patient-reported outcomes

KW - pruritus

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=84958182074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958182074&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2015.10.043

DO - 10.1016/j.jaad.2015.10.043

M3 - Article

C2 - 26777100

AN - SCOPUS:84958182074

VL - 74

SP - 491

EP - 498

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -